ABSTRACT
(TKI) only, 2 conventional chemotherapy only, and 2 chemotherapy plus TKI. Responses to other therapies were variable. Conclusions. DFS after treatment for DFSP is strongly predicted by tumor depth in the primary setting and margin status in recurrent tumors. The treatment for DFSP in the primary or recurrent setting is excision with negative margins, resulting in low recurrence rates and infrequent metastatic spread. Multimodality treatment, especially TKI use, can be effective, but is not curative.
Dermatofibrosarcoma protuberans (DFSP) is a rare, superficial sarcoma characterized by its infiltrative growth pattern. 1, 2 It is predisposed to local recurrence (LR) after primary resection, has low metastatic potential, and patients rarely die from DFSP. 3 The classically described histologic pattern of DFSP can transform into a more aggressive fibrosarcomatous variant (FS-DFSP). 4, 5 This subtype is more aggressive and displays higher metastatic potential. On a molecular level, 90% of DFSPs possess a unique translocation that fuses the highly expressed collagen type-1 alpha-1 (COL1A1) gene with the platelet-derived growth factor-beta (PDGFb) chain, providing the rationale for the use of imatinib mesylate (IM) and other tyrosine kinase inhibitors (TKIs) in the treatment DFSP. [6] [7] [8] [9] [10] The standard treatment for DFSP is surgical excision with wide margins, which has resulted in low (\15%) rates of LR. [11] [12] [13] The use of other therapies, including radiation therapy (RT) and TKIs, has been described, both in the neoadjuvant and adjuvant settings, as well as for definitive treatment in patients unfit for surgery. 8, [14] [15] [16] [17] [18] The use of multimodality therapy is not standard, and its effectiveness in cases of microscopically positive margins after excision is not known.
Several single-institution reports, including our own, have identified clinicopathologic factors associated with disease-free survival (DFS). 12, 13, 16, [19] [20] [21] In 2000, we reported that margin status and fibrosarcomatous transformation (FS-DFSP) predicted recurrence in 159 patients with DFSP. 12 The rare nature of the tumor, coupled with the low rates of recurrence, has limited such analyses from making definitive, consistent conclusions. The advent of targeted medical therapy in the form of TKIs may further alter such findings. In the current analysis, we investigated our institutional experience with DFSP in a modern series to clarify factors associated with DFS and the effectiveness of multimodality therapy.
METHODS
A total of 244 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY) for primary or recurrent DFSP from July 1982 to July 2009 were identified from our prospectively maintained clinical sarcoma database (approximately 3% of all sarcoma cases) of patients presenting to MSKCC with a diagnosis of DFSP and receiving treatment (all modalities) at our institution. Clinical and pathologic variables obtained from the database included: patient age, sex, presentation date, presentation status (primary vs. recurrent), tumor variables (location, size, depth, grade, histology, invasion), treatment information (surgery, chemotherapy, RT), date of last follow-up, recurrence, and vital status. This project was approved by the MSKCC Institutional Review Board (IRB).
Patients with recurrent DFSP were initially treated at an outside institution (OSH) and referred to MSKCC for subsequent care. Recurrent disease was defined as histologically proven tumor arising within or adjacent to the previous tumor bed C6 months after previous treatment.
Patients were followed at 3-to 6-month intervals for the 1st year, then every 6-12 months thereafter. Follow-up consisted of a clinical exam, with laboratory and radiology studies performed to evaluate suspicious clinical findings at the discretion of the attending physician. Response to chemotherapy was graded using World Health Organization (WHO) criteria. Follow-up information was updated to July 2009.
Patients who presented with primary (1°-DFSP) versus locally recurrent (LR-DFSP) disease were analyzed separately. Patient characteristics were described for the 2 groups and Fisher exact test or the Wilcoxon rank sum test were used to compare the distributions.
DFS, which counts all LR, distant recurrence (DR), and death as events, was defined as the length of time from the date of surgery at our institution to the time the event was captured in our database or last follow-up. Because of the very small number of DR, LR-free survival (counting LR/ death as events) would be essentially the same as DFS. DFS curves were generated using the Kaplan-Meier method. Univariate analysis on DFS was performed using the log-rank test. Variables significant at the 0.05 level in the univariate setting were entered to a multivariate model, using the Cox proportional hazard analysis.
We also ran a separate analysis treating LR as events of primary interest and death as competing risk events. Univariate analysis on LR was performed using Gray's test to compare cumulative incidence curves for LR. No multivariate analysis was performed because of the low incidence of LR.
The competing risk analysis was performed using the R package (www.r-project.org); the other analyses were performed using SAS Software, Version 9.1 (Cary, NC). One patient presented with 1°-DFSP and underwent a palliative R2 resection. These 4 patients were excluded from subsequent analysis. Table 1 summarizes the remaining 240 patients included in the analysis, subdivided by presentation status (80% 1°-DFSP, 20% LR-DFSP). There was equal distribution between males and females. The majority (74%) of lesions were asymptomatic. Extremity location was the most common site of presentation with 71 (29%) and 55 tumors (23%) occurring in the upper and lower extremities, respectively. There were 76 tumors (31%) on the trunk, 33 tumors (14%) on the head/neck, and 5 tumors (2%) in other locations. Histologic review of all cases by a dedicated sarcoma pathologist (M.H.) found the presence of FS-DFSP in 35 cases (15%). A total of 185 patients (77%) had superficial tumors, while 54 (23%) had deep tumors invading the fascia directly beneath the primary lesion.
RESULTS

Clinicopathologic and Treatment-Related Data
Patients with LR-DFSP were older (46 years) than those with 1°-DFSP (39 years). There were no differences between 1°-and LR-DFSP with respect to gender, tumor location, depth, histology, and margin.
Complete surgical excision was achieved in all cases. Postoperatively, microscopically negative margins (R0 resection) were achieved in 169 patients (86%) in the primary group and 35 patients (80%) in the LR group. All patients were treated with wide surgical excision. There were no patients in this series treated with Mohs micrographic surgery.
Disease-Free Survival
During the follow-up, there were 17 events [9 LR, 1 DR (in a patient that also had LR), and 8 deaths] in the primary group and 9 events (5 LR, 1 DR, and 3 deaths) in the LR group (Table 1) , corresponding to 70 and 47% DFS for primary and LR patients, respectively, at the time of last follow-up.
In the primary group, of the 9 patients with a LR, 1 patient had a subsequent LR that was managed with reexcision and is currently NED. Pathologic review demonstrated an R0 resection after all 3 excisions, but his tumor demonstrated the FS-DFSP variant. In the LR group, 3 patients had subsequent LRs, one of whom developed DR and died of disease.
Patients presenting with 1°-DFSP had significantly improved median DFS (P = 0.043; Fig. 1a ) and longer times to local recurrence (P = 0.04; Fig. 1b ) when 
Univariate and Multivariate Analysis
For patients presenting with 1°-DFSP, tumor depth and location significantly predicted recurrence (P = 0.024 and 0.049, respectively, by log-rank test). For patients presenting with LR-DFSP, a negative margin (R0) resection significantly predicted DFS (HR = 22.43, 95% CI 2.61-192.94, P \ 0.001). On multivariate analysis, depth remained a significant predictor of recurrence (HR = 3.14, 95% CI 1.18-8.32, P = 0.022) and location (extremity vs others) was marginally significant (HR = 2.94, 95% CI 0.96-9.09, P = 0.059) for patients with 1°-DFSP. Table 2 summarizes the results of the univariate and multivariate analysis. Figures 2 and 3 illustrate Kaplan-Meier curves of DFS for primary and LR patients, respectively, stratified by the aforementioned significant variables (tumor location and depth for primary patients, and margin status for LR patients).
When univariate analysis is performed using the competing risk method, depth (P = 0.08) is marginally significant for 1°-DFSP. For LR patients, margin status (P \ 0.001) remains significantly associated with recurrence.
Other Therapy
Of the 244 patients who presented with or developed locally advanced or metastatic disease, 22 were treated with nonsurgical therapy: 14 RT, 4 TKIs, 2 conventional chemotherapy, and 2 TKIs and conventional chemotherapy. Table 3 summarizes the results of our institutional experience with systemic treatment.
All patients who received RT for DFSP had their treatment initiated at OSHs. There were 10 patients who were treated with adjuvant external beam radiation at an OSH after a positive margin excision. Of these 10 patients, 9 were evaluated at our institution and underwent reexcision with negative margins and are all NED with an average of 34 ± 9 months of follow-up. Of note, 7 of these 9 patients had viable, residual disease in their re-excision specimens. One patient was recommended re-excision and elected observation and is NED after 28 months of followup. One patient received adjuvant RT for a \1 mm margin and is NED after 37 months of follow-up. One patient had multifocal recurrence of a groin DFSP and underwent RT, followed by re-excision at our institution, and died of other causes 17 months later with no evidence of recurrence. Two patients received intraoperative brachytherapy at an OSH during an incomplete excision. Both underwent reexcision to negative margins at our institution and are NED after 14 and 20 months of follow-up.
Two patients were treated with conventional chemotherapy alone. One was treated with cisplatin and paclitaxel at an outside institution after a close margin. The patient underwent re-excision at our institution and is currently NED after 49 months of follow-up. Another patient was 1 of the 3 who presented with metastatic disease and was treated with systemic chemotherapy (cisplatin, mitomycin, and vinblastine). This tumor was not responsive to any treatment modality, and the patient died of disease. Two other patients with metastatic disease were treated conventional chemotherapy and TKIs. One of these patients demonstrated a partial (50%) response to IM, but progressed after 6 months and died of disease 3 months later. The other patient is alive with disease (AWD) after a partial (50%) response to IM for a duration of 12 months prior to progression and addition of etoposide and cyclophosphamide.
There were 4 patients treated with TKIs alone. One who developed metastatic disease was treated with IM and demonstrated a partial (75%) response and is currently AWD after 9 months of follow-up. One patient had an unresectable, multiply recurrent lesion that partially responded to IM (50% for 36 months) and sorafenib (stable disease during current 12 months of treatment). One patient with LR and metastatic DFSP was unresponsive to both IM and sorafenib and died of disease. A 4th patient was treated with preoperative IM after presenting with a large LR. This patient had a partial response (33%), followed by excision with negative margins and is currently NED after 31 months of follow-up. To summarize our experience with TKIs, we have had 5 partial responses in 6 patients treated with IM with a duration of response from 6-36 months. In the 2 patients treated with sorafenib after failure of IM, 1 had a partial response and 1 progressed.
DISCUSSION DFSP is a rare soft tissue malignancy that often shows extensive local invasion but rarely metastasizes. 22 It can lead to significant morbidity from repeated surgical excisions, but infrequently leads to death. 3, 5, 12, 13, 20 The combination of the rarity of DFSP and the low number of recurrence events has precluded any large, randomized trials to address the optimal management of DFSP. To our knowledge, this series of 244 patients with DFSP is one of the largest in the literature and represents an update of our institutional experience from 2000. 12 Our reported rates of R0 resection (86 and 80% for primary LR tumors, respectively) and DFS (92 and 87% at 5 years for primary and recurrent tumors, respectively) are consistent with other large series, including a report of 218 patients from Fiore et al. in 2005 (crude cumulative incidence [CCI] of sarcoma-specific mortality of 1.5 and 2.8% at 5 and 10 years, respectively, and CCI of local relapse of 3.0 and 4.2% at 5 and 10 years, respectively). 13 In contrast to our current findings, Fiore et al. report a CCI of sarcomaspecific mortality of 6.2% in patients presenting with a LR tumor. This observation is likely the result of differences in patient selection, demographics, and referral patterns between our 2 institutions.
Our rates of microscopically positive margins after resection for 1°-DFSP (14%) and LR-DFSP (20%) are also consistent with other series. 13, 20 The slight variation between series may also reflect differences in tumor pathology, as our current series contains a high percentage (17%) of patients with the more aggressive FS-DFSP variant. Interestingly, however, and in contrast to our previously published series, the presence of FS-DFSP histology did not predict DFS. This may be explained by the more modern cohort of patients analyzed in the present series (1982-2009 vs. 1950-1998) . Patients prior to 1982 were not included in the present series, partly due to both the inability to independently verify their histologic and treatment profiles and the desire to analyze a modern cohort of prospectively studied patients that represents current treatment standards for DFSP.
Our institutional practice is to achieve gross negative margins of 2-3 cm whenever possible. This leads to the high rates of R0 resections achieved in our series, which is our goal of any operation for DFSP. We do not routinely use frozen section analysis to assess margin status, as our sarcoma pathologists have found it unreliable in differentiating scattered spindle cells in normal dermis from minimal-residual DFSP cells. 23, 24 Our series is not able to comment on the use of Mohs surgery in the treatment of DFSP, as there were no patients in our database either treated with Mohs at an outside institution and referred to MSKCC for follow-up or patients offered Mohs surgery as a treatment modality at MSKCC for 1°-DFSP. We feel the aforementioned limitation of frozen section analysis for DFSP also limits the application of Mohs surgery in the treatment of DFSP.
Our finding that tumor location significantly predicts DFS on univariate, but not multivariate, analysis for 1°-DFSP may reflect the small number of events in these 196 patients (Table 2) . Conceptually, with larger numbers of patients, tumor location may predict DFS, as wider margins, and thus lower rates of LR, may be more easily obtainable on the trunk/thorax versus the extremities and head/neck.
The finding that tumor depth significantly predicts DFS on both univariate and multivariate analysis is in line with the histopathologic observation that DFSP, especially when invasive beneath fascial plains, is likely biologically more aggressive than those infiltrating through subcutaneous fat. 25, 26 Thus, wide margins in both the radial and deep planes are critical to achieve tumor clearance, and the deep fascia should always be excised. We found no correlation between deep tumors and the FS-DFSP histology. We found that margin status (R0 vs. R1) significantly predicted DFS in patients treated for LR-DFSP, with a HR of 22.43 (Table 2 ). This is also consistent with other published series. Of the 9 patients who had microscopically positive margins after resection of LR-DFSP, 3 (33%) had a subsequent recurrence on follow-up, all of which were managed by re-excision. At the time of last follow-up (32, 61 , and 48 months after re-excision), all 3 were NED. Because of this low rate of observed LR after positive margins and the ability to treat such recurrences with repeat excision, it has been our practice to closely follow these patients. This is in contrast to other institutions that will routinely use immediate re-excision of microscopically positive margins and/or adjuvant RT in such cases, with similar rates of both local and distant recurrence. 14, 16, 21 However, in our series, only 33% of patients with microscopically positive margins developed a clinically significant recurrence, and re-excision and RT carries significant morbidity. The use of adjuvant radiation treatment for all patients with microscopically positive margins will result in overtreatment of at least 2 patients for every 1 that will possibly benefit in our 33% of patients with microscopically positive margins that require any such intervention. So, the potential benefit versus the morbidity of re-resection and RT versus observation and directed treatment of clinical recurrences must be considered. It is possible, however, that longer follow-up will reveal increased rates of LR in this patient group. As Fig. 1 demonstrates, there are a large number of recurrences after 5 years, owing to the indolent nature of DFSP. Thus, close 8, 28 Our experience with TKIs mirrors the literature: we had 5 of 6 patients with PRs to IM with durations of response from 6 to 36 months. One patient progressed. In 2 patients treated with sorafenib, 1 had a PR and 1 progressed.
In total, there are approximately 60 described cases of TKI treatment for DFSP in 14 publications. 1 The largest series, presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting, contains 25 patients, with responses in 36% of patients with a median tumor decrease of 20%. 17 The Phase II IM Target Exploration Consortium B2225 Study evaluated the activity of IM treating advanced IM-sensitive tumors, which included 12 patients with DFSP. 29 Of these, 4 patients (33%) had complete responses, 6 patients had PRs (50%), 1 patient (8%) had progression of disease (PD), and 1 patient (8%) was lost to follow-up. The median time to progression was 23.9 months. In a recent pooled analysis of 24 patients from 2 phase II clinical trials of IM in the treatment of DFSP (16 patients from the European Organization for Research and Treatment of Cancer [EORTC] and 8 patients from the Southwest Oncology Group [SWOG]), 9 patients (38%) had PRs, 8 patients (33%) had stable disease, 4 patients (17%) had PD, and 3 patients (13%) were lost to follow-up. 30 The median time to progression was 20.4 months. Thus, similar to their use in gastrointestinal stromal tumors (GISTs), TKIs are not considered curative in DFSP. 31 Our practice is to use TKIs in cases of locally advanced/unresectable cases, metastatic disease, or in patients unfit for surgery. Currently, several clinical trials, including multicentric phase II studies, are recruiting patients with DFSP, along with other solid malignancies, to further define the indications for TKI use. 32 In summary, DFSP is a locally aggressive tumor that can usually be cured with wide excision. LR tumors can lead to significant morbidity, but rarely lead to death. Tumor depth significantly predicts recurrence in cases of 1°-DFSP, while margin status predicts recurrence in cases of LR-DFSP. The majority of cases of recurrent DFSP are cured with reexcision. The treatment of 1°-DFSP and recurrent-DFSP should be an R0 resection whenever possible. TKIs are effective in treating DFSP and should be used for the infrequent cases of unresectable or metastatic disease.
